RenovoRx, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 26.2K | $26.41K | 0.00% | Unchanged | 2026-03-31 |
| RenTech | quant | 13.0K | $13.13K | 0.00% | Trimmed-88.9% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-14 | -0.08 | -0.08 | -4.34% |
| 2026-03-30 | -0.08 | -0.08 | — |
| 2025-11-13 | -0.08 | -0.08 | — |
| 2025-08-14 | -0.08 | -0.08 | +5.88% |
| 2025-05-15 | -0.07 | -0.08 | -6.67% |
| 2025-04-01 | -0.12 | -0.12 | +4.00% |
| 2024-11-13 | -0.12 | -0.10 | +16.67% |
| 2024-08-13 | -0.11 | -0.10 | +9.09% |
| 2024-05-10 | -0.13 | -0.07 | +46.15% |
| 2024-04-01 | -0.30 | -0.30 | +1.64% |
| 2023-11-13 | -0.28 | -0.13 | +53.57% |
| 2023-08-16 | -0.29 | -0.22 | +24.14% |
| 2023-05-12 | -0.21 | -0.36 | -67.44% |
| 2023-03-02 | -0.26 | -0.23 | +11.54% |
| 2022-11-14 | -0.29 | -0.24 | +17.24% |
| 2022-08-12 | -0.28 | -0.29 | -1.75% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| RNXT | +2.94% | +6.82% | +8.21% | -35.99% |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | -0.02% | +11.64% | +11.66% | -48.61% |